Solventum Corp SOLV
Solventum Corp (SOLV) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $8.3B at a 18.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.06 — grey zone (between the usual thresholds). A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-06 | UBS | Buy (main) |
| 2026-08-06 | Piper Sandler | Overweight (main) |
| 2026-08-06 | Wedbush | Outperform (main) |
| 2026-08-06 | Keybanc | Overweight (main) |
| 2026-08-06 | Stifel | Buy (main) |
| 2026-08-06 | BTIG | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.051 |
| Retained earnings / assets | 0.126 |
| EBIT / assets | 0.153 |
| Equity / liabilities | 0.546 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SOLV | Solventum Corp | 6/9 | 2.34 | 8.9 | +0.9% |
| BAX | BAXTER INTERNATIONAL INC | 5/9 | 3.86 | — | +5.7% |
| RMD | RESMED INC | 8/9 | 8.65 | 20.7 | +9.8% |
| DXCM | DEXCOM INC | 7/9 | 4.98 | 32.4 | +15.6% |
| MMED | MiniMed Group, Inc. | 3/9 | 4.28 | — | +14.3% |
| WST | WEST PHARMACEUTICAL SERVICES INC | 7/9 | 9.34 | 47.2 | +6.3% |
| GMED | GLOBUS MEDICAL INC | 7/9 | 10.06 | 21.8 | +16.7% |
About Solventum Corp
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.
FAQ
Is SOLV financially healthy?
Solventum Corp's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does SOLV pay a dividend?
No, Solventum Corp does not currently pay a dividend.
How profitable is SOLV?
In FY2025, Solventum Corp had a net margin of 18.7% and a return on equity of 30.8%.
What is SOLV's P/E ratio?
Solventum Corp's trailing price-to-earnings (P/E) ratio is about 8.9×, based on its latest annual earnings.
What is the analyst price target for SOLV?
The average Wall-Street price target for Solventum Corp is $93.92, about 10.1% above the recent price, from 13 analysts (consensus: buy).
Is SOLV a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Solventum Corp: a Piotroski F-score of 6/9, an Altman Z″ in the grey zone, a P/E of about 8.9×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.